Key Drivers
- Strong profitability
- Weak cash flow
- Premium valuation
AIAI Summary
WST has re-rated from a low-drama healthcare compounder into a premium-priced growth-and-execution story, so biologics/GLP-1 demand and raised guidance support the thesis but the stock now looks fully valued unless management can sustain growth and convert earnings into stronger free cash flow.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong profitability
- •Weak cash flow
- •Premium valuation
WST remains highly profitable and conservatively financed, but recent cash flow softness and a rich valuation limit upside.
Price Behavior
Key Price Behavior Insights:
- •Uptrend intact
- •Fast extension
- •Breakout support
WST's strong rise over the last month confirms an intermediate uptrend, but after the fast move from about $324 to $366 it looks short-term extended, with $359-$360 and $350-$351 as near support and $365-$370 as resistance.
Sharp rally from about $324 on 2026-06-17 to about $366 on 2026-07-02 suggests short-term extension risk
Sentiment & News
Key News Insights:
- •Earnings momentum
- •Demand tailwinds
- •Portfolio reshaping
WST is drawing momentum from strong earnings, GLP-1 and biologics demand, while its SmartDose® divestiture adds a strategic portfolio shift and raises questions about how long the rally can last.
The news is modestly positive for WST, as strong fundamental demand supports the stock even as the SmartDose sale signals ongoing business optimization
Similar Companies in Healthcare
Other companies in the same sector with AI ratings